Managing cytopenia associated with anti-HCV therapy Dorota Kozielewicz, Dorota Dybowska Medical Science Review - Hepatologia 2009; 9 51-53 aaICID: 902242
Article type: Review article
IC™ Value: 3.04
Abstract provided by Publisher
The recommended therapy for chronic hepatitis C is the combination of pegylated interferon alpha and ribavirin. The optimal drug doses have a direct influence on achieving a sustain virologic response (SVR). This therapy is associated with several adverse events, such as hematological side effects. The most frequent adverse effect is anemia, followed neutro- and thrombocytopenia. Using hematological growth factors allows the administration of a full course of the antiviral drugs and thereby achievement of a higher rate of SVR.